浅析Firehawk药物洗脱支架临床应用评价

Analysis of clinical application of Firehawk drug eluting stent

目的初步探索Firehawk雷帕霉素药物洗脱支架在临床应用中的效益分析。方法回顾2015年1月至2015年12月期间分别接受Firehawk支架及Fierbird2支架介入治疗的89例冠心病患者,通过分析对比一般情况、介入相关情况及随访相关指标,初步探索Firehawk雷帕霉素药物洗脱支架在临床应用中的安全性及疗效。结果两组在支架直径、支架长度及支架释放压力方面均无统计学差异(P>0.05),而Firehawk组支架数低于Firebird2组(P<0.05);两组随访期间均无全因死亡、心脏性死亡、急性心梗及主要不良心脏事件发生;复查造影者亦均无支架内再狭窄、靶病变血运重建及晚期血栓形成;两组造影复查率均较高且无统计学差异(P>0.05);两组均有再发心绞痛病例,Firehawk组较Firebird2组无统计学差异(P>0.05);两组在随访时间(月)方面有统计学差异(P<0.05),其中Firehawk组低于Firebird2组。结论 Firehawk支架在冠脉介入治疗中安全有效。

Objective To explore the clinical efficacy of rapamycin drug eluting stent Firehawk. Methods Eighty-nine patients in the department from January 2015 to December 2015 were included. These patients were divided into two groups,one is Firehawk group and another is Firebird2 group. To study and contrast the clinical efficacy of Firehawk and Firebird2 drug eluting stent through the analysis and comparison of general situation,the relevant situation and related indicators. Results There was no significant difference in the stent diameter,stent length and stent release pressure between the two groups（ P 0. 05）. But the number of stents in Firehawk group was significantly lower than that in Firebird2 group（ P 0. 05）. No death,cardiac death,acute myocardial infarction,and major adverse cardiac events occurred during the follow-up period in the two groups. No stent restenosis,target lesion revascularization,and late thrombosis were also reviewed. Two groups of contrast examination rate were higher and no statistical difference（ P 0. 05）. In the two groups,there were some patients with angina pectoris,there was no significant difference between the Firehawk group and the Firebird2 group（ P 0. 05）. The two groups in the follow-up period（ months）,there were statistically significant differences,in which the Firehawk group was lower than the Firebird2 group（ P 0. 05）. Conclusion Firehawk stent is safe and effective in percutaneous coronary intervention.